相似文献
1
Novel therapeutic agents against cancer stem cells of chronic myeloid leukemia.
Anticancer Agents Med Chem. 2010 Feb;10(2):111-5. doi: 10.2174/187152010790909326.
2
Inhibitory effects of omacetaxine on leukemic stem cells and BCR-ABL-induced chronic myeloid leukemia and acute lymphoblastic leukemia in mice.
Leukemia. 2009 Aug;23(8):1446-54. doi: 10.1038/leu.2009.52. Epub 2009 Mar 26.
3
Dual inhibition of Bcr-Abl and Hsp90 by C086 potently inhibits the proliferation of imatinib-resistant CML cells.
Clin Cancer Res. 2015 Feb 15;21(4):833-43. doi: 10.1158/1078-0432.CCR-13-3317. Epub 2014 Dec 11.
4
Characterization of cancer stem cells in chronic myeloid leukaemia.
Biochem Soc Trans. 2007 Nov;35(Pt 5):1347-51. doi: 10.1042/BST0351347.
5
The Alox5 gene is a novel therapeutic target in cancer stem cells of chronic myeloid leukemia.
Cell Cycle. 2009 Nov 1;8(21):3488-92. doi: 10.4161/cc.8.21.9852. Epub 2009 Nov 19.
6
Novel HDAC inhibitor MAKV-8 and imatinib synergistically kill chronic myeloid leukemia cells via inhibition of BCR-ABL/MYC-signaling: effect on imatinib resistance and stem cells.
Clin Epigenetics. 2020 May 19;12(1):69. doi: 10.1186/s13148-020-00839-z.
7
New Bcr-Abl inhibitors in chronic myeloid leukemia: keeping resistance in check.
Expert Opin Investig Drugs. 2008 Jun;17(6):865-78. doi: 10.1517/13543784.17.6.865.
8
Activity of omacetaxine mepesuccinate against ponatinib-resistant BCR-ABL-positive cells.
Blood. 2013 Oct 24;122(17):3086-8. doi: 10.1182/blood-2013-04-494773.
9
BMS-214662 potently induces apoptosis of chronic myeloid leukemia stem and progenitor cells and synergizes with tyrosine kinase inhibitors.
Blood. 2008 Mar 1;111(5):2843-53. doi: 10.1182/blood-2007-09-112573. Epub 2007 Dec 21.
10
Omacetaxine mepesuccinate in chronic myeloid leukemia.
Expert Opin Pharmacother. 2014 Nov;15(16):2397-405. doi: 10.1517/14656566.2014.964642.
引用本文的文献
1
Characterization of the bone marrow niche in patients with chronic myeloid leukemia identifies CXCL14 as a new therapeutic option.
Blood. 2023 Jul 6;142(1):73-89. doi: 10.1182/blood.2022016896.
2
Ovatodiolide targets chronic myeloid leukemia stem cells by epigenetically upregulating hsa-miR-155, suppressing the BCR-ABL fusion gene and dysregulating the PI3K/AKT/mTOR pathway.
Oncotarget. 2017 Dec 14;9(3):3267-3277. doi: 10.18632/oncotarget.23231. eCollection 2018 Jan 9.
3
Hsp90 N- and C-terminal double inhibition synergistically suppresses Bcr-Abl-positive human leukemia cells.
Oncotarget. 2017 Feb 7;8(6):10025-10036. doi: 10.18632/oncotarget.14324.
4
Omacetaxine mepesuccinate: a new treatment option for patients with chronic myelogenous leukemia.
J Adv Pract Oncol. 2013 Jul;4(4):257-62.
5
Effects of quercetin on hedgehog signaling in chronic myeloid leukemia KBM7 cells.
Chin J Integr Med. 2014 Oct;20(10):776-81. doi: 10.1007/s11655-014-1817-3. Epub 2014 Jun 13.
6
Disrupting BCR-ABL in combination with secondary leukemia-specific pathways in CML cells leads to enhanced apoptosis and decreased proliferation.
Mol Pharm. 2013 Jan 7;10(1):270-7. doi: 10.1021/mp300405n. Epub 2012 Dec 18.
7
Chronic myeloid leukemia stem cells in the era of targeted therapies: resistance, persistence and long-term dormancy.
Oncotarget. 2011 Sep;2(9):713-27. doi: 10.18632/oncotarget.333.
8
Developments in antivirals against influenza, smallpox and hemorrhagic fever viruses.
Expert Opin Investig Drugs. 2011 Feb;20(2):239-54. doi: 10.1517/13543784.2011.547852.
9
First-line treatment for chronic myeloid leukemia: dasatinib, nilotinib, or imatinib.
J Hematol Oncol. 2010 Nov 26;3:47. doi: 10.1186/1756-8722-3-47.
10
The tissue-specific stem cell as a target for chemoprevention.
Stem Cell Rev Rep. 2011 Jun;7(2):307-14. doi: 10.1007/s12015-010-9205-7.
本文引用的文献
1
BMS-214662 induces mitochondrial apoptosis in chronic myeloid leukemia (CML) stem/progenitor cells, including CD34+38- cells, through activation of protein kinase Cbeta.
Blood. 2009 Nov 5;114(19):4186-96. doi: 10.1182/blood-2009-05-219550. Epub 2009 Sep 8.
2
Following the hedgehog to new cancer therapies.
N Engl J Med. 2009 Sep 17;361(12):1202-5. doi: 10.1056/NEJMe0906092. Epub 2009 Sep 2.
3
Loss of the Alox5 gene impairs leukemia stem cells and prevents chronic myeloid leukemia.
Nat Genet. 2009 Jul;41(7):783-92. doi: 10.1038/ng.389. Epub 2009 Jun 7.
4
Inhibitory effects of omacetaxine on leukemic stem cells and BCR-ABL-induced chronic myeloid leukemia and acute lymphoblastic leukemia in mice.
Leukemia. 2009 Aug;23(8):1446-54. doi: 10.1038/leu.2009.52. Epub 2009 Mar 26.
5
Hedgehog signalling is essential for maintenance of cancer stem cells in myeloid leukaemia.
Nature. 2009 Apr 9;458(7239):776-9. doi: 10.1038/nature07737.
6
beta-Catenin is essential for survival of leukemic stem cells insensitive to kinase inhibition in mice with BCR-ABL-induced chronic myeloid leukemia.
Leukemia. 2009 Jan;23(1):109-16. doi: 10.1038/leu.2008.262. Epub 2008 Sep 25.
7
Expansion of Bcr-Abl-positive leukemic stem cells is dependent on Hedgehog pathway activation.
Cancer Cell. 2008 Sep 9;14(3):238-49. doi: 10.1016/j.ccr.2008.08.003.
8
Stems cells and the pathways to aging and cancer.
Cell. 2008 Feb 22;132(4):681-96. doi: 10.1016/j.cell.2008.01.036.
9
BMS-214662 potently induces apoptosis of chronic myeloid leukemia stem and progenitor cells and synergizes with tyrosine kinase inhibitors.
Blood. 2008 Mar 1;111(5):2843-53. doi: 10.1182/blood-2007-09-112573. Epub 2007 Dec 21.
10
Loss of beta-catenin impairs the renewal of normal and CML stem cells in vivo.
Cancer Cell. 2007 Dec;12(6):528-41. doi: 10.1016/j.ccr.2007.11.003.
Zotero 插件